Table 2

 Change in indices of disease activity after treatment with etanercept

Time (No of patients evaluated*)
Baseline (314)Month 1 (242)Month 3 (225)Month 6 (203)Month 12 (152)Month 18 (99)Month 24 (78)Month 30 (42)
Compared with pretreatment levels, significant improvement was noted in all data and all points of time: p<0.0001 for all except for swollen joint count and ESR at 30 months: p<0.0005; duration of morning stiffness at 30 months: p<0.001; CHAQ at 30 months: p<0.01; Wilcoxon matched pairs test.
*Only data from patients with JIA who underwent assessment at the respective visit are included.
†The range of scores for the CHAQ is 0–3 (0 = best, 3 = worst).
‡A 100 mm scale was used to assess the patient’s and physician’s global assessment of disease activity (0 = best, 100 = worst).
CHAQ, child health assessment questionnaire; ESR, erythrocyte sedimentation rate; JIA, juvenile idiopathic arthritis; LOM, limitation of movement.
Number of swollen joints8.4 (9.0)4.5 (7.0)3.3 (5.6)3.6 (6.5)2.6 (4.7)3.6 (7.5)2.4 (3.9)3.3 (6.1)
Patients with no swollen joint11%23%36%45%51%50%43%48%
Number of tender joints9.1 (9.5)3.0 (6.5)2.2 (5.5)2.6 (6.7)1.7 (3.5)2.7 (6.1)1.8 (3.3)1.7 (3.1)
Patients with no tender joint7%46%52%55%58%63%59%57%
Number of joints with LOM11.8 (11.8)8.0 (11.3)7.2 (10.6)7.7 (11.6)7.1 (8.9)7.6 (10.9)8.2 (9.8)10.0 (10.7)
Patients with no joint with LOM5%15%16%18%16%24%13%15%
Number of active joints10.2 (9.5)5.3 (7.9)3.8 (6.3)4.4 (7.7)3.1 (4.6)4.8 (8.5)3.9 (4.6)4.6 (6.9)
Patients with no active joint6%22%32%37%40%42%29%39%
Morning stiffness (minutes)45 (65)12 (30)8 (19)6 (17)7 (23)8 (31)8 (24)4 (10)
Patients with no morning stiffness29%66%73%75%79%81%78%85%
CHAQ score†1.0 (0.8)NANA0.5 (0.6)0.4 (0.6)0.5 (0.6)0.4 (0.6)0.5 (0.7)
Patients with CHAQ score of 011%NANA32%34%39%40%49%
Patient’s global assessment‡56 (27)24 (22)19 (19)18 (20)16 (18)17 (23)17 (18)12 (16)
Patient’s global <10 mm6%38%46%48%54%56%53%61%
Physician assessment‡67 (25)32 (26)26 (26)24 (25)20 (23)23 (27)20 (21)20 (24)
Physician’s global <10 mm2%27%40%42%52%44%39%57%
ESR40 (30)19 (21)19 (21)18 (19)17 (17)18 (21)17 (13)19 (17)
Patients with ESR <16 mm/h22%62%63%64%68%66%61%54%